CATALYST PHARMA PTR
CATALYST PHARMA PTR operates in Diversified Metals & Mining.
CATALYST PHARMA PTR (CN2) - Net Assets
Latest net assets as of September 2024: €660.94 Million EUR
Based on the latest financial reports, CATALYST PHARMA PTR (CN2) has net assets worth €660.94 Million EUR as of September 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€772.01 Million) and total liabilities (€111.07 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €660.94 Million |
| % of Total Assets | 85.61% |
| Annual Growth Rate | 38.7% |
| 5-Year Change | 342.64% |
| 10-Year Change | N/A |
| Growth Volatility | 45.27 |
CATALYST PHARMA PTR - Net Assets Trend (2016–2023)
This chart illustrates how CATALYST PHARMA PTR's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for CATALYST PHARMA PTR (2016–2023)
The table below shows the annual net assets of CATALYST PHARMA PTR from 2016 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | €387.88 Million | +29.11% |
| 2022-12-31 | €300.42 Million | +45.25% |
| 2021-12-31 | €206.83 Million | +21.95% |
| 2020-12-31 | €169.60 Million | +93.54% |
| 2019-12-31 | €87.63 Million | +72.55% |
| 2018-12-31 | €50.78 Million | -37.28% |
| 2017-12-31 | €80.96 Million | +105.97% |
| 2016-12-31 | €39.31 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to CATALYST PHARMA PTR's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 22942007000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €121.27 Million | 31.27% |
| Other Components | €266.61 Million | 68.73% |
| Total Equity | €387.88 Million | 100.00% |
CATALYST PHARMA PTR Competitors by Market Cap
The table below lists competitors of CATALYST PHARMA PTR ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
GAME HOURS Inc.
TWO:6626
|
$204.64K |
|
Coop Opsparing Moderat
CO:COIMRA
|
$204.66K |
|
IS Dongseo Co. Ltd.
KQ:010780
|
$204.71K |
|
SKF AB
STU:SKFA
|
$204.71K |
|
TAIYO YUDEN - Dusseldorf Stock Exchang
DU:TYC1
|
$204.44K |
|
NTT DATA - Dusseldorf Stock Exchang
DU:NT5
|
$204.38K |
|
TRANSCOSMOS
BE:TSQ
|
$204.31K |
|
ABENGOA YIELD
MU:AY3
|
$204.30K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CATALYST PHARMA PTR's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 300,421,000 to 387,881,000, a change of 87,460,000 (29.1%).
- Net income of 71,410,000 contributed positively to equity growth.
- Other factors increased equity by 16,050,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €71.41 Million | +18.41% |
| Other Changes | €16.05 Million | +4.14% |
| Total Change | €- | 29.11% |
Book Value vs Market Value Analysis
This analysis compares CATALYST PHARMA PTR's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.55x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 25.47x to 5.55x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €0.79 | €20.11 | x |
| 2018-12-31 | €0.49 | €20.11 | x |
| 2019-12-31 | €0.85 | €20.11 | x |
| 2020-12-31 | €1.63 | €20.11 | x |
| 2021-12-31 | €2.01 | €20.11 | x |
| 2022-12-31 | €2.85 | €20.11 | x |
| 2023-12-31 | €3.62 | €20.11 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CATALYST PHARMA PTR utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 18.41%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 17.93%
- • Asset Turnover: 0.85x
- • Equity Multiplier: 1.21x
- Recent ROE (18.41%) is above the historical average (1.26%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -45.98% | 0.00% | 0.00x | 1.06x | €-22.00 Million |
| 2017 | -22.74% | 0.00% | 0.00x | 1.05x | €-26.51 Million |
| 2018 | -66.96% | -6800.70% | 0.01x | 1.19x | €-39.08 Million |
| 2019 | 36.37% | 31.16% | 0.91x | 1.28x | €23.11 Million |
| 2020 | 44.21% | 62.97% | 0.62x | 1.13x | €58.02 Million |
| 2021 | 19.09% | 28.03% | 0.59x | 1.15x | €18.80 Million |
| 2022 | 27.65% | 38.79% | 0.57x | 1.25x | €53.04 Million |
| 2023 | 18.41% | 17.93% | 0.85x | 1.21x | €32.62 Million |
Industry Comparison
This section compares CATALYST PHARMA PTR's net assets metrics with peer companies in the Other industry.
Industry Context
- Industry: Other
- Average net assets among peers: $107,279,526,363
- Average return on equity (ROE) among peers: 7.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CATALYST PHARMA PTR (CN2) | €660.94 Million | -45.98% | 0.17x | $204.44K |
| HORIBA (01H) | $204.49 Billion | 10.42% | 0.82x | $973.51K |
| Tokyu Corporation (01T) | $747.05 Billion | 9.38% | 2.03x | $93.98K |
| GUANGZHOU AUTO -H- (02G) | $77.92 Billion | 13.99% | 0.70x | $4.23K |
| MOSAIC (02M) | $9.37 Billion | -11.39% | 1.06x | $267.55K |
| MOSAIC (02M.SG) (02M) | $10.72 Billion | 9.59% | 0.71x | $264.31K |
| CHINA JO-JO DRGSTRS (04CN.SG) (04CN) | $22.74 Million | -14.04% | 3.68x | $1.51 Million |
| KRAKATAU STEEL -B- (07K) | $587.19 Million | 7.57% | 5.43x | $166.88 |
| CN MODERN DAIRY (07M.SG) (07M) | $8.04 Billion | 9.58% | 0.94x | $1.66K |
| TOURMALINE OIL (08T) | $13.69 Billion | 32.78% | 0.38x | $376.57K |
| ASIA CASSAVA RESOUR (0ACS) | $913.15 Million | 2.86% | 1.55x | $343.89 |